Imperial College London
Alternate

ProfessorMichaelSeckl

Faculty of Medicine, Department of Surgery & Cancer

Professor of Molecular Cancer Medicine
 
 
 
//

Contact

 

+44 (0)20 3311 1421m.seckl

 
 
//

Location

 

08Cyclotron buildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Braga:2015:10.1111/1471-0528.13617,
author = {Braga, A and Maestá, I and Short, D and Savage, P and Harvey, R and Seckl, MJ},
doi = {10.1111/1471-0528.13617},
journal = {BJOG - An International Journal of Obstetrics and Gynaecology},
pages = {1330--1335},
title = {Hormonal contraceptive use before hCG remission does not increase the risk of gestational trophoblastic neoplasia following complete hydatidiform mole: a historical database review},
url = {http://dx.doi.org/10.1111/1471-0528.13617},
volume = {123},
year = {2015}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - OBJECTIVE: To re-evaluate the safety of hormonal contraceptives (HC) after uterine evacuation of complete hydatidiform mole (CHM). DESIGN: Historical database review. SETTING: Charing Cross Hospital Gestational Trophoblastic Disease Centre, London, United Kingdom. POPULATION: Two thousand four hundred and twenty-three women with CHM of whom 154 commenced HC while their human chorionic gonadotropin (hCG) was still elevated, followed between 2003 and 2012. METHODS: We compared time to hCG remission between HC users and nonusers. The relationship between HC use and gestational trophoblastic neoplasia (GTN) development was assessed. The relationship between HC use and a high International Federation of Gynecology and Obstetrics (FIGO) risk score was determined. MAIN OUTCOME MEASURES: Time to hCG remission, risk of developing postmolar GTN and proportion of women with high FIGO risk score. RESULTS: No relationship was observed between HC use with mean time to hCG remission (HC users versus non-users: 12 weeks in both, P = 0.19), GTN development (HC users versus non-users: 20.1 and 16.7%, P = 0.26) or high-risk FIGO score (HC users versus nonusers: 0% and 8%, P = 0.15). Moreover, no association between HC and GTN development was found, even when an age-adjusted model was used (OR = 1.37, 95% CI 0.91-2.08, P = 0.13). CONCLUSIONS: The use of current HC is not associated with development of postmolar GTN or delayed time to hCG remission. Therefore, HC can be safely used to prevent a new conception following CHM regardless of hCG level. TWEETABLE ABSTRACT: Non-concurrent cohort study to re-evaluate the safety of low dose HCs after uterine evacuation of CHM.
AU  - Braga,A
AU  - Maestá,I
AU  - Short,D
AU  - Savage,P
AU  - Harvey,R
AU  - Seckl,MJ
DO  - 10.1111/1471-0528.13617
EP  - 1335
PY  - 2015///
SN  - 1470-0328
SP  - 1330
TI  - Hormonal contraceptive use before hCG remission does not increase the risk of gestational trophoblastic neoplasia following complete hydatidiform mole: a historical database review
T2  - BJOG - An International Journal of Obstetrics and Gynaecology
UR  - http://dx.doi.org/10.1111/1471-0528.13617
UR  - http://hdl.handle.net/10044/1/26729
VL  - 123
ER  -
Download